Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype

Calla M. Olson, Yanke Liang, Alan Leggett, Woojun D. Park, Lianbo Li, Caitlin E. Mills, Selma Z. Elsarrag, Scott B. Ficarro, Tinghu Zhang, Robert Düster, Matthias Geyer, Taebo Sim, Jarrod A. Marto, Peter K. Sorger, Kenneth D Westover, Charles Y. Lin, Nicholas Kwiatkowski, Nathanael S. Gray

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cyclin-dependent kinase 7 (CDK7) regulates both cell cycle and transcription, but its precise role remains elusive. We previously described THZ1, a CDK7 inhibitor, which dramatically inhibits superenhancer-associated gene expression. However, potent CDK12/13 off-target activity obscured CDK7s contribution to this phenotype. Here, we describe the discovery of a highly selective covalent CDK7 inhibitor. YKL-5-124 causes arrest at the G1/S transition and inhibition of E2F-driven gene expression; these effects are rescued by a CDK7 mutant unable to covalently engage YKL-5-124, demonstrating on-target specificity. Unlike THZ1, treatment with YKL-5-124 resulted in no change to RNA polymerase II C-terminal domain phosphorylation; however, inhibition could be reconstituted by combining YKL-5-124 and THZ531, a selective CDK12/13 inhibitor, revealing potential redundancies in CDK control of gene transcription. These findings highlight the importance of CDK7/12/13 polypharmacology for anti-cancer activity of THZ1 and posit that selective inhibition of CDK7 may be useful for treatment of cancers marked by E2F misregulation. Olson et al. describe the development and characterization of YKL-5-124, a potent, selective, and covalent CDK7 inhibitor. YKL-5-124 displays biochemical and cellular selectivity for CDK7 over CDK12/13, structurally related kinases. CDK7 inhibition by YKL-5-124 induces a strong cell-cycle arrest and a surprisingly weak effect on RNA Pol II phosphorylation.

Original languageEnglish (US)
Pages (from-to)792-803.e10
JournalCell Chemical Biology
Volume26
Issue number6
DOIs
StatePublished - Jun 20 2019

Fingerprint

Cyclin-Dependent Kinases
Cell Cycle
Cells
Phenotype
Phosphorylation
RNA Polymerase II
Transcription
Gene expression
Polypharmacology
RNA Polymerase III
Gene Expression
Cell Cycle Checkpoints
Redundancy
Neoplasms
Phosphotransferases
Genes
Display devices

Keywords

  • cancer
  • cell cycle
  • drug discovery
  • gene expression
  • small-molecule inhibitor
  • transcription

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Olson, C. M., Liang, Y., Leggett, A., Park, W. D., Li, L., Mills, C. E., ... Gray, N. S. (2019). Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chemical Biology, 26(6), 792-803.e10. https://doi.org/10.1016/j.chembiol.2019.02.012

Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. / Olson, Calla M.; Liang, Yanke; Leggett, Alan; Park, Woojun D.; Li, Lianbo; Mills, Caitlin E.; Elsarrag, Selma Z.; Ficarro, Scott B.; Zhang, Tinghu; Düster, Robert; Geyer, Matthias; Sim, Taebo; Marto, Jarrod A.; Sorger, Peter K.; Westover, Kenneth D; Lin, Charles Y.; Kwiatkowski, Nicholas; Gray, Nathanael S.

In: Cell Chemical Biology, Vol. 26, No. 6, 20.06.2019, p. 792-803.e10.

Research output: Contribution to journalArticle

Olson, CM, Liang, Y, Leggett, A, Park, WD, Li, L, Mills, CE, Elsarrag, SZ, Ficarro, SB, Zhang, T, Düster, R, Geyer, M, Sim, T, Marto, JA, Sorger, PK, Westover, KD, Lin, CY, Kwiatkowski, N & Gray, NS 2019, 'Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype', Cell Chemical Biology, vol. 26, no. 6, pp. 792-803.e10. https://doi.org/10.1016/j.chembiol.2019.02.012
Olson, Calla M. ; Liang, Yanke ; Leggett, Alan ; Park, Woojun D. ; Li, Lianbo ; Mills, Caitlin E. ; Elsarrag, Selma Z. ; Ficarro, Scott B. ; Zhang, Tinghu ; Düster, Robert ; Geyer, Matthias ; Sim, Taebo ; Marto, Jarrod A. ; Sorger, Peter K. ; Westover, Kenneth D ; Lin, Charles Y. ; Kwiatkowski, Nicholas ; Gray, Nathanael S. / Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. In: Cell Chemical Biology. 2019 ; Vol. 26, No. 6. pp. 792-803.e10.
@article{8218e8d617444cee8ded8393f2ef9800,
title = "Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype",
abstract = "Cyclin-dependent kinase 7 (CDK7) regulates both cell cycle and transcription, but its precise role remains elusive. We previously described THZ1, a CDK7 inhibitor, which dramatically inhibits superenhancer-associated gene expression. However, potent CDK12/13 off-target activity obscured CDK7s contribution to this phenotype. Here, we describe the discovery of a highly selective covalent CDK7 inhibitor. YKL-5-124 causes arrest at the G1/S transition and inhibition of E2F-driven gene expression; these effects are rescued by a CDK7 mutant unable to covalently engage YKL-5-124, demonstrating on-target specificity. Unlike THZ1, treatment with YKL-5-124 resulted in no change to RNA polymerase II C-terminal domain phosphorylation; however, inhibition could be reconstituted by combining YKL-5-124 and THZ531, a selective CDK12/13 inhibitor, revealing potential redundancies in CDK control of gene transcription. These findings highlight the importance of CDK7/12/13 polypharmacology for anti-cancer activity of THZ1 and posit that selective inhibition of CDK7 may be useful for treatment of cancers marked by E2F misregulation. Olson et al. describe the development and characterization of YKL-5-124, a potent, selective, and covalent CDK7 inhibitor. YKL-5-124 displays biochemical and cellular selectivity for CDK7 over CDK12/13, structurally related kinases. CDK7 inhibition by YKL-5-124 induces a strong cell-cycle arrest and a surprisingly weak effect on RNA Pol II phosphorylation.",
keywords = "cancer, cell cycle, drug discovery, gene expression, small-molecule inhibitor, transcription",
author = "Olson, {Calla M.} and Yanke Liang and Alan Leggett and Park, {Woojun D.} and Lianbo Li and Mills, {Caitlin E.} and Elsarrag, {Selma Z.} and Ficarro, {Scott B.} and Tinghu Zhang and Robert D{\"u}ster and Matthias Geyer and Taebo Sim and Marto, {Jarrod A.} and Sorger, {Peter K.} and Westover, {Kenneth D} and Lin, {Charles Y.} and Nicholas Kwiatkowski and Gray, {Nathanael S.}",
year = "2019",
month = "6",
day = "20",
doi = "10.1016/j.chembiol.2019.02.012",
language = "English (US)",
volume = "26",
pages = "792--803.e10",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype

AU - Olson, Calla M.

AU - Liang, Yanke

AU - Leggett, Alan

AU - Park, Woojun D.

AU - Li, Lianbo

AU - Mills, Caitlin E.

AU - Elsarrag, Selma Z.

AU - Ficarro, Scott B.

AU - Zhang, Tinghu

AU - Düster, Robert

AU - Geyer, Matthias

AU - Sim, Taebo

AU - Marto, Jarrod A.

AU - Sorger, Peter K.

AU - Westover, Kenneth D

AU - Lin, Charles Y.

AU - Kwiatkowski, Nicholas

AU - Gray, Nathanael S.

PY - 2019/6/20

Y1 - 2019/6/20

N2 - Cyclin-dependent kinase 7 (CDK7) regulates both cell cycle and transcription, but its precise role remains elusive. We previously described THZ1, a CDK7 inhibitor, which dramatically inhibits superenhancer-associated gene expression. However, potent CDK12/13 off-target activity obscured CDK7s contribution to this phenotype. Here, we describe the discovery of a highly selective covalent CDK7 inhibitor. YKL-5-124 causes arrest at the G1/S transition and inhibition of E2F-driven gene expression; these effects are rescued by a CDK7 mutant unable to covalently engage YKL-5-124, demonstrating on-target specificity. Unlike THZ1, treatment with YKL-5-124 resulted in no change to RNA polymerase II C-terminal domain phosphorylation; however, inhibition could be reconstituted by combining YKL-5-124 and THZ531, a selective CDK12/13 inhibitor, revealing potential redundancies in CDK control of gene transcription. These findings highlight the importance of CDK7/12/13 polypharmacology for anti-cancer activity of THZ1 and posit that selective inhibition of CDK7 may be useful for treatment of cancers marked by E2F misregulation. Olson et al. describe the development and characterization of YKL-5-124, a potent, selective, and covalent CDK7 inhibitor. YKL-5-124 displays biochemical and cellular selectivity for CDK7 over CDK12/13, structurally related kinases. CDK7 inhibition by YKL-5-124 induces a strong cell-cycle arrest and a surprisingly weak effect on RNA Pol II phosphorylation.

AB - Cyclin-dependent kinase 7 (CDK7) regulates both cell cycle and transcription, but its precise role remains elusive. We previously described THZ1, a CDK7 inhibitor, which dramatically inhibits superenhancer-associated gene expression. However, potent CDK12/13 off-target activity obscured CDK7s contribution to this phenotype. Here, we describe the discovery of a highly selective covalent CDK7 inhibitor. YKL-5-124 causes arrest at the G1/S transition and inhibition of E2F-driven gene expression; these effects are rescued by a CDK7 mutant unable to covalently engage YKL-5-124, demonstrating on-target specificity. Unlike THZ1, treatment with YKL-5-124 resulted in no change to RNA polymerase II C-terminal domain phosphorylation; however, inhibition could be reconstituted by combining YKL-5-124 and THZ531, a selective CDK12/13 inhibitor, revealing potential redundancies in CDK control of gene transcription. These findings highlight the importance of CDK7/12/13 polypharmacology for anti-cancer activity of THZ1 and posit that selective inhibition of CDK7 may be useful for treatment of cancers marked by E2F misregulation. Olson et al. describe the development and characterization of YKL-5-124, a potent, selective, and covalent CDK7 inhibitor. YKL-5-124 displays biochemical and cellular selectivity for CDK7 over CDK12/13, structurally related kinases. CDK7 inhibition by YKL-5-124 induces a strong cell-cycle arrest and a surprisingly weak effect on RNA Pol II phosphorylation.

KW - cancer

KW - cell cycle

KW - drug discovery

KW - gene expression

KW - small-molecule inhibitor

KW - transcription

UR - http://www.scopus.com/inward/record.url?scp=85066984722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066984722&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2019.02.012

DO - 10.1016/j.chembiol.2019.02.012

M3 - Article

VL - 26

SP - 792-803.e10

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 6

ER -